Smith+Nephew expands next-generation handheld robotic-assisted CORI™ Surgical System into total hip arthroplasty with RI.HIP NAVIGATION
LONDON, Jan. 26, 2022 /PRNewswire/ — Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces the expansion of indications on its CORI Surgical System – the industry’s most advanced and efficient1,* handheld robotic solution in total knee arthroplasty1,*,† – to now include total hip arthroplasty (THA). Smith+Nephew’s RI.HIP NAVIGATION – designed to help maximize accuracy and reproducibility by delivering patient-specific component alignment for THA – is now available for use on its CORI System.
Last year, a new study concluded that computer-guided technology for THA significantly reduced the risk of revision2 and increased patient satisfaction2 when using Smith+Nephew implants. The first of its kind study used data from the world’s largest arthroplasty register (National Joint Registry of England, Wales and Northern Ireland) to investigate the effect of computer-guided THA surgery on implant survivorship.2 The data reported on THA surgery performed using Smith+Nephew hip replacement components implanted for osteoarthritis since 2003 and was presented at the 2021 World Arthroplasty Congress. The results demonstrated:
- A significantly lower revision rate at 10 years with computer-guided (1.06%) vs. conventional THA (3.88%; p=0.005)2
- A 55% lower risk of revision at 10 years with computer-guided vs. conventional THA (p=0.038)2, and
- Significantly higher patient satisfaction in the computer-guided group compared to conventional THA (p=0.003)2
“The addition of RI.HIP NAVIGATION on the CORI System further strengthens Smith+Nephew’s Real Intelligence digital ecosystem and underscores our commitment to advancing clinical outcomes in total hip arthroplasty,” said Randy Kilburn, Executive Vice President & General Manager, Reconstruction, Robotics and Digital Surgery for Smith+Nephew. “We look forward to offering the possibility of further improving patient outcomes and satisfaction to a broader surgeon community with the rapidly expanding adoption of our CORI Surgical System.”
Smith+Nephew’s RI.HIP NAVIGATION recently received 510(k) clearance from the United States Food and Drug Administration for use on its CORI Surgical System. Software installations will start immediately for a limited number of hospitals and Ambulatory Surgery Centers (ASCs) in the United States with broad commercial availability later in 2022. It will be introduced in various European and Asia Pacific markets once regulatory authorizations are finalized.
To learn more about Smith+Nephew’s Real Intelligence ecosystem, please visit www.real-intelligence.com
References
1. Smith+Nephew 2020. CORI and NAVIO System Technical Specification Comparison. Internal Report. ER0488 REV B.
2. Davis ET, McKinney KD, Kamali A, Kuljaca S, Pagkalos J. Computer guided total hip arthroplasty is associated with a reduced risk of revision and increased patient satisfaction. An analysis of a single manufacturer acetabular components from the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man. Poster presented at: World Arthroplasty Congress Virtual Meeting; April 22-24, 2021
*Compared to conventional techniques
†Compared to NAVIO Surgical System
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew plc
